We are analyzing https://link.springer.com/article/10.1007/s00384-004-0726-x.

Title:
Immune responses in advanced colorectal cancer following repeated intradermal vaccination with the anti-CEA murine monoclonal antibody, PR1A3: results of a phase I study | International Journal of Colorectal Disease
Description:
Background and aims The aim was to determine the toxicity, clinical and immune responses to the murine monoclonal anti-carcinoembryonic antigen (CEA) antibody, PR1A3, in patients with advanced colorectal cancer. Materials and methods Fifteen patients with advanced colorectal cancer received either 0.5-, 1.0- or 5.0-mg doses of PR1A3 mixed with 10% w/v Alum adjuvant (Superfos Biosector, Denmark) intradermally at 4-week intervals for 3 months. Patient serum was assessed for anti-idiotypic (Ab2), anti-anti-idiotypic (Ab3) and human anti-mouse antibody (HAMA) reactivity. Peripheral blood mononuclear cell (PBMC) proliferation with phytohaemagglutinin (PHA), CEA and PR1A3, stimulated IL-2, IL-4 and IFN-γ levels and PR1A3-stimulated IL-2 receptor expression during immunotherapy were determined. Comparisons were made with 16 age-matched controls without malignant disease. Results Hyperimmune sera from 12 of the 15 patients showed Ab2 reactivity with no detectable Ab3 responses. Strong HAMA reactivity was recorded in 7 of the 15 cases with no adverse clinical effect. Delayed-type hypersensitivity (DTH) responses developed in 12 of the 15 patients. Pre-treatment PBMC proliferation with PHA was subnormal in each patient compared with controls, becoming normal (or supranormal) in all patients during immunisation (P<0.001). PBMC proliferation with CEA and PR1A3 increased during immunotherapy (P<0.001) along with stimulated production of IL-2, IFN-γ and IL-2 receptor expression. Progressive disease was observed in 14 of the 15 patients with minimal toxicity. Conclusion PR1A3 generated limited idiotypic responses but robust DTH reactivity in most patients. In vitro PBMC proliferation with mitogens and recall antigens is greatly increased during the course of immunisation, with a shift in stimulated cytokine profile.
Website Age:
28 years and 1 months (reg. 1997-05-29).

Matching Content Categories {📚}

Health & Fitness
Education
Science

Content Management System {📝}

What CMS is link.springer.com built with?

Custom-built

No common CMS systems were detected on Link.springer.com, and no known web development framework was identified.

Traffic Estimate {📈}

What is the average monthly size of link.springer.com audience?

🌠 Phenomenal Traffic: 5M - 10M visitors per month

Based on our best estimate, this website will receive around 5,000,019 visitors per month in the current month.
However, some sources were not loaded, we suggest to reload the page to get complete results.

check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush

How Does Link.springer.com Make Money? {💸}

We can't tell how the site generates income.

Some websites aren't about earning revenue; they're built to connect communities or raise awareness. There are numerous motivations behind creating websites. This might be one of them. Link.springer.com might be making money, but it's not detectable how they're doing it.

Keywords {🔍}

cancer, google, scholar, cas, pubmed, monoclonal, antibody, colorectal, article, patients, antibodies, immune, cells, human, pra, study, immunol, research, responses, advanced, access, therapy, phase, wadhwa, carcinoma, int, privacy, cookies, content, journal, murine, zbar, bodmer, antigen, cea, adjuvant, cell, proliferation, immunotherapy, carcinoembryonic, mellstedt, clin, immunother, hospital, publish, search, disease, results, wilkinson, ross,

Topics {✒️}

antibody-dependent monocyte-mediated cytotoxicity advanced colorectal carcinoma—long-lasting anti-idiotype antibody vaccine month download article/chapter anti-tumour antibodies anti-anti-idiotypic antibodies cell-bound carcinoembryonic antigen steroid-sensitive nephrotic syndrome recombinant dna-derived molecules human anti-mouse antibody 111in-labelled monoclonal antibody anti-idiotype immunization humoral responses directed related subjects cea-specific monoclonal antibodies anti-anti-idiotypic related factor alterations article international journal monoclonal antibody therapy peripheral blood pre-treatment pbmc proliferation full article pdf t-helper 1 populations multicenter randomized trial anti-idiotypic network privacy choices/manage cookies human colorectal tumors monoclonal antibody specific carcinoembryonic antigen defined antigen–antibody complexes human colorectal carcinoma complement-dependent cytotoxicity mouse monoclonal antibody antibody dependent cytolysis colorectal cancer treated human colorectal epithelium monoclonal antibody ebm11 monoclonal antibody immunoconjugates mouse monoclonal antibodies il-2 receptor expression advanced colorectal cancer pd-1 monoclonal antibodies durrant lg drug-antibody conjugates monoclonal antibody 17-1a advanced colorectal cancers recurrent colorectal cancer naturally occurring antibodies 3rd international conference cytokine cell biology

Questions {❓}

May induction of ab1-reactive T cells and anti-anti-idiotypic antibodies (ab3) lead to tumor regression after mAb therapy?

Schema {🗺️}

WebPage:
      mainEntity:
         headline:Immune responses in advanced colorectal cancer following repeated intradermal vaccination with the anti-CEA murine monoclonal antibody, PR1A3: results of a phase I study
         description:The aim was to determine the toxicity, clinical and immune responses to the murine monoclonal anti-carcinoembryonic antigen (CEA) antibody, PR1A3, in patients with advanced colorectal cancer. Fifteen patients with advanced colorectal cancer received either 0.5-, 1.0- or 5.0-mg doses of PR1A3 mixed with 10% w/v Alum adjuvant (Superfos Biosector, Denmark) intradermally at 4-week intervals for 3 months. Patient serum was assessed for anti-idiotypic (Ab2), anti-anti-idiotypic (Ab3) and human anti-mouse antibody (HAMA) reactivity. Peripheral blood mononuclear cell (PBMC) proliferation with phytohaemagglutinin (PHA), CEA and PR1A3, stimulated IL-2, IL-4 and IFN-γ levels and PR1A3-stimulated IL-2 receptor expression during immunotherapy were determined. Comparisons were made with 16 age-matched controls without malignant disease. Hyperimmune sera from 12 of the 15 patients showed Ab2 reactivity with no detectable Ab3 responses. Strong HAMA reactivity was recorded in 7 of the 15 cases with no adverse clinical effect. Delayed-type hypersensitivity (DTH) responses developed in 12 of the 15 patients. Pre-treatment PBMC proliferation with PHA was subnormal in each patient compared with controls, becoming normal (or supranormal) in all patients during immunisation (P<0.001). PBMC proliferation with CEA and PR1A3 increased during immunotherapy (P<0.001) along with stimulated production of IL-2, IFN-γ and IL-2 receptor expression. Progressive disease was observed in 14 of the 15 patients with minimal toxicity. PR1A3 generated limited idiotypic responses but robust DTH reactivity in most patients. In vitro PBMC proliferation with mitogens and recall antigens is greatly increased during the course of immunisation, with a shift in stimulated cytokine profile.
         datePublished:2005-04-30T00:00:00Z
         dateModified:2005-04-30T00:00:00Z
         pageStart:403
         pageEnd:414
         sameAs:https://doi.org/10.1007/s00384-004-0726-x
         keywords:
            Monoclonal antibody therapy
            Immunotherapy
            Anti-idiotypic antibodies
            Surgery
            Internal Medicine
            Gastroenterology
            Hepatology
            Proctology
         image:
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00384-004-0726-x/MediaObjects/s00384-004-0726-xfhc1.jpg
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00384-004-0726-x/MediaObjects/s00384-004-0726-xfhc2.jpg
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00384-004-0726-x/MediaObjects/s00384-004-0726-xflb3.gif
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00384-004-0726-x/MediaObjects/s00384-004-0726-xflb4.gif
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00384-004-0726-x/MediaObjects/s00384-004-0726-xfmb5.gif
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00384-004-0726-x/MediaObjects/s00384-004-0726-xflb6.gif
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00384-004-0726-x/MediaObjects/s00384-004-0726-xflb7.gif
         isPartOf:
            name:International Journal of Colorectal Disease
            issn:
               1432-1262
               0179-1958
            volumeNumber:20
            type:
               Periodical
               PublicationVolume
         publisher:
            name:Springer-Verlag
            logo:
               url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
               type:ImageObject
            type:Organization
         author:
               name:A. P. Zbar
               affiliation:
                     name:Hammersmith Hospital
                     address:
                        name:Academic Department of Colorectal Surgery, Hammersmith Hospital, London, UK
                        type:PostalAddress
                     type:Organization
                     name:Queen Elizabeth Hospital
                     address:
                        name:School of Clinical Medicine and Research, University of the West Indies, Queen Elizabeth Hospital, Barbados
                        type:PostalAddress
                     type:Organization
               email:[email protected]
               type:Person
               name:H. Thomas
               affiliation:
                     name:Royal Surrey County Hospital
                     address:
                        name:St. Luke’s Cancer Centre, Royal Surrey County Hospital, Guildford, UK
                        type:PostalAddress
                     type:Organization
               type:Person
               name:R. W. Wilkinson
               affiliation:
                     name:Imperial Cancer Research Fund
                     address:
                        name:Applied Development Laboratory, Imperial Cancer Research Fund, London, UK
                        type:PostalAddress
                     type:Organization
               type:Person
               name:M. Wadhwa
               affiliation:
                     name:National Institute for Biologic Standards and Control
                     address:
                        name:National Institute for Biologic Standards and Control, Hertfordshire, UK
                        type:PostalAddress
                     type:Organization
               type:Person
               name:K. N. Syrigos
               affiliation:
                     name:St. George’s Hospital
                     address:
                        name:Antisoma Plc, St. George’s Hospital, London, UK
                        type:PostalAddress
                     type:Organization
               type:Person
               name:E. L. Ross
               affiliation:
                     name:Imperial Cancer Research Fund
                     address:
                        name:Applied Development Laboratory, Imperial Cancer Research Fund, London, UK
                        type:PostalAddress
                     type:Organization
               type:Person
               name:P. Dilger
               affiliation:
                     name:National Institute for Biologic Standards and Control
                     address:
                        name:National Institute for Biologic Standards and Control, Hertfordshire, UK
                        type:PostalAddress
                     type:Organization
               type:Person
               name:T. G. Allen-Mersh
               affiliation:
                     name:Chelsea and Westminster Hospital
                     address:
                        name:Department of Gastrointestinal Surgery, Chelsea and Westminster Hospital, London, UK
                        type:PostalAddress
                     type:Organization
               type:Person
               name:W. A. Kmiot
               affiliation:
                     name:Hammersmith Hospital
                     address:
                        name:Academic Department of Colorectal Surgery, Hammersmith Hospital, London, UK
                        type:PostalAddress
                     type:Organization
               type:Person
               name:A. A. Epenetos
               affiliation:
                     name:St. George’s Hospital
                     address:
                        name:Antisoma Plc, St. George’s Hospital, London, UK
                        type:PostalAddress
                     type:Organization
               type:Person
               name:D. Snary
               affiliation:
                     name:Imperial Cancer Research Fund
                     address:
                        name:Applied Development Laboratory, Imperial Cancer Research Fund, London, UK
                        type:PostalAddress
                     type:Organization
               type:Person
               name:W. F. Bodmer
               affiliation:
                     name:Institute of Molecular Medicine
                     address:
                        name:Cancer and Immunogenetics Laboratory, Imperial Cancer Research Fund, Institute of Molecular Medicine, Oxford, UK
                        type:PostalAddress
                     type:Organization
               type:Person
         isAccessibleForFree:
         hasPart:
            isAccessibleForFree:
            cssSelector:.main-content
            type:WebPageElement
         type:ScholarlyArticle
      context:https://schema.org
ScholarlyArticle:
      headline:Immune responses in advanced colorectal cancer following repeated intradermal vaccination with the anti-CEA murine monoclonal antibody, PR1A3: results of a phase I study
      description:The aim was to determine the toxicity, clinical and immune responses to the murine monoclonal anti-carcinoembryonic antigen (CEA) antibody, PR1A3, in patients with advanced colorectal cancer. Fifteen patients with advanced colorectal cancer received either 0.5-, 1.0- or 5.0-mg doses of PR1A3 mixed with 10% w/v Alum adjuvant (Superfos Biosector, Denmark) intradermally at 4-week intervals for 3 months. Patient serum was assessed for anti-idiotypic (Ab2), anti-anti-idiotypic (Ab3) and human anti-mouse antibody (HAMA) reactivity. Peripheral blood mononuclear cell (PBMC) proliferation with phytohaemagglutinin (PHA), CEA and PR1A3, stimulated IL-2, IL-4 and IFN-γ levels and PR1A3-stimulated IL-2 receptor expression during immunotherapy were determined. Comparisons were made with 16 age-matched controls without malignant disease. Hyperimmune sera from 12 of the 15 patients showed Ab2 reactivity with no detectable Ab3 responses. Strong HAMA reactivity was recorded in 7 of the 15 cases with no adverse clinical effect. Delayed-type hypersensitivity (DTH) responses developed in 12 of the 15 patients. Pre-treatment PBMC proliferation with PHA was subnormal in each patient compared with controls, becoming normal (or supranormal) in all patients during immunisation (P<0.001). PBMC proliferation with CEA and PR1A3 increased during immunotherapy (P<0.001) along with stimulated production of IL-2, IFN-γ and IL-2 receptor expression. Progressive disease was observed in 14 of the 15 patients with minimal toxicity. PR1A3 generated limited idiotypic responses but robust DTH reactivity in most patients. In vitro PBMC proliferation with mitogens and recall antigens is greatly increased during the course of immunisation, with a shift in stimulated cytokine profile.
      datePublished:2005-04-30T00:00:00Z
      dateModified:2005-04-30T00:00:00Z
      pageStart:403
      pageEnd:414
      sameAs:https://doi.org/10.1007/s00384-004-0726-x
      keywords:
         Monoclonal antibody therapy
         Immunotherapy
         Anti-idiotypic antibodies
         Surgery
         Internal Medicine
         Gastroenterology
         Hepatology
         Proctology
      image:
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00384-004-0726-x/MediaObjects/s00384-004-0726-xfhc1.jpg
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00384-004-0726-x/MediaObjects/s00384-004-0726-xfhc2.jpg
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00384-004-0726-x/MediaObjects/s00384-004-0726-xflb3.gif
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00384-004-0726-x/MediaObjects/s00384-004-0726-xflb4.gif
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00384-004-0726-x/MediaObjects/s00384-004-0726-xfmb5.gif
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00384-004-0726-x/MediaObjects/s00384-004-0726-xflb6.gif
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00384-004-0726-x/MediaObjects/s00384-004-0726-xflb7.gif
      isPartOf:
         name:International Journal of Colorectal Disease
         issn:
            1432-1262
            0179-1958
         volumeNumber:20
         type:
            Periodical
            PublicationVolume
      publisher:
         name:Springer-Verlag
         logo:
            url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
            type:ImageObject
         type:Organization
      author:
            name:A. P. Zbar
            affiliation:
                  name:Hammersmith Hospital
                  address:
                     name:Academic Department of Colorectal Surgery, Hammersmith Hospital, London, UK
                     type:PostalAddress
                  type:Organization
                  name:Queen Elizabeth Hospital
                  address:
                     name:School of Clinical Medicine and Research, University of the West Indies, Queen Elizabeth Hospital, Barbados
                     type:PostalAddress
                  type:Organization
            email:[email protected]
            type:Person
            name:H. Thomas
            affiliation:
                  name:Royal Surrey County Hospital
                  address:
                     name:St. Luke’s Cancer Centre, Royal Surrey County Hospital, Guildford, UK
                     type:PostalAddress
                  type:Organization
            type:Person
            name:R. W. Wilkinson
            affiliation:
                  name:Imperial Cancer Research Fund
                  address:
                     name:Applied Development Laboratory, Imperial Cancer Research Fund, London, UK
                     type:PostalAddress
                  type:Organization
            type:Person
            name:M. Wadhwa
            affiliation:
                  name:National Institute for Biologic Standards and Control
                  address:
                     name:National Institute for Biologic Standards and Control, Hertfordshire, UK
                     type:PostalAddress
                  type:Organization
            type:Person
            name:K. N. Syrigos
            affiliation:
                  name:St. George’s Hospital
                  address:
                     name:Antisoma Plc, St. George’s Hospital, London, UK
                     type:PostalAddress
                  type:Organization
            type:Person
            name:E. L. Ross
            affiliation:
                  name:Imperial Cancer Research Fund
                  address:
                     name:Applied Development Laboratory, Imperial Cancer Research Fund, London, UK
                     type:PostalAddress
                  type:Organization
            type:Person
            name:P. Dilger
            affiliation:
                  name:National Institute for Biologic Standards and Control
                  address:
                     name:National Institute for Biologic Standards and Control, Hertfordshire, UK
                     type:PostalAddress
                  type:Organization
            type:Person
            name:T. G. Allen-Mersh
            affiliation:
                  name:Chelsea and Westminster Hospital
                  address:
                     name:Department of Gastrointestinal Surgery, Chelsea and Westminster Hospital, London, UK
                     type:PostalAddress
                  type:Organization
            type:Person
            name:W. A. Kmiot
            affiliation:
                  name:Hammersmith Hospital
                  address:
                     name:Academic Department of Colorectal Surgery, Hammersmith Hospital, London, UK
                     type:PostalAddress
                  type:Organization
            type:Person
            name:A. A. Epenetos
            affiliation:
                  name:St. George’s Hospital
                  address:
                     name:Antisoma Plc, St. George’s Hospital, London, UK
                     type:PostalAddress
                  type:Organization
            type:Person
            name:D. Snary
            affiliation:
                  name:Imperial Cancer Research Fund
                  address:
                     name:Applied Development Laboratory, Imperial Cancer Research Fund, London, UK
                     type:PostalAddress
                  type:Organization
            type:Person
            name:W. F. Bodmer
            affiliation:
                  name:Institute of Molecular Medicine
                  address:
                     name:Cancer and Immunogenetics Laboratory, Imperial Cancer Research Fund, Institute of Molecular Medicine, Oxford, UK
                     type:PostalAddress
                  type:Organization
            type:Person
      isAccessibleForFree:
      hasPart:
         isAccessibleForFree:
         cssSelector:.main-content
         type:WebPageElement
["Periodical","PublicationVolume"]:
      name:International Journal of Colorectal Disease
      issn:
         1432-1262
         0179-1958
      volumeNumber:20
Organization:
      name:Springer-Verlag
      logo:
         url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
         type:ImageObject
      name:Hammersmith Hospital
      address:
         name:Academic Department of Colorectal Surgery, Hammersmith Hospital, London, UK
         type:PostalAddress
      name:Queen Elizabeth Hospital
      address:
         name:School of Clinical Medicine and Research, University of the West Indies, Queen Elizabeth Hospital, Barbados
         type:PostalAddress
      name:Royal Surrey County Hospital
      address:
         name:St. Luke’s Cancer Centre, Royal Surrey County Hospital, Guildford, UK
         type:PostalAddress
      name:Imperial Cancer Research Fund
      address:
         name:Applied Development Laboratory, Imperial Cancer Research Fund, London, UK
         type:PostalAddress
      name:National Institute for Biologic Standards and Control
      address:
         name:National Institute for Biologic Standards and Control, Hertfordshire, UK
         type:PostalAddress
      name:St. George’s Hospital
      address:
         name:Antisoma Plc, St. George’s Hospital, London, UK
         type:PostalAddress
      name:Imperial Cancer Research Fund
      address:
         name:Applied Development Laboratory, Imperial Cancer Research Fund, London, UK
         type:PostalAddress
      name:National Institute for Biologic Standards and Control
      address:
         name:National Institute for Biologic Standards and Control, Hertfordshire, UK
         type:PostalAddress
      name:Chelsea and Westminster Hospital
      address:
         name:Department of Gastrointestinal Surgery, Chelsea and Westminster Hospital, London, UK
         type:PostalAddress
      name:Hammersmith Hospital
      address:
         name:Academic Department of Colorectal Surgery, Hammersmith Hospital, London, UK
         type:PostalAddress
      name:St. George’s Hospital
      address:
         name:Antisoma Plc, St. George’s Hospital, London, UK
         type:PostalAddress
      name:Imperial Cancer Research Fund
      address:
         name:Applied Development Laboratory, Imperial Cancer Research Fund, London, UK
         type:PostalAddress
      name:Institute of Molecular Medicine
      address:
         name:Cancer and Immunogenetics Laboratory, Imperial Cancer Research Fund, Institute of Molecular Medicine, Oxford, UK
         type:PostalAddress
ImageObject:
      url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
Person:
      name:A. P. Zbar
      affiliation:
            name:Hammersmith Hospital
            address:
               name:Academic Department of Colorectal Surgery, Hammersmith Hospital, London, UK
               type:PostalAddress
            type:Organization
            name:Queen Elizabeth Hospital
            address:
               name:School of Clinical Medicine and Research, University of the West Indies, Queen Elizabeth Hospital, Barbados
               type:PostalAddress
            type:Organization
      email:[email protected]
      name:H. Thomas
      affiliation:
            name:Royal Surrey County Hospital
            address:
               name:St. Luke’s Cancer Centre, Royal Surrey County Hospital, Guildford, UK
               type:PostalAddress
            type:Organization
      name:R. W. Wilkinson
      affiliation:
            name:Imperial Cancer Research Fund
            address:
               name:Applied Development Laboratory, Imperial Cancer Research Fund, London, UK
               type:PostalAddress
            type:Organization
      name:M. Wadhwa
      affiliation:
            name:National Institute for Biologic Standards and Control
            address:
               name:National Institute for Biologic Standards and Control, Hertfordshire, UK
               type:PostalAddress
            type:Organization
      name:K. N. Syrigos
      affiliation:
            name:St. George’s Hospital
            address:
               name:Antisoma Plc, St. George’s Hospital, London, UK
               type:PostalAddress
            type:Organization
      name:E. L. Ross
      affiliation:
            name:Imperial Cancer Research Fund
            address:
               name:Applied Development Laboratory, Imperial Cancer Research Fund, London, UK
               type:PostalAddress
            type:Organization
      name:P. Dilger
      affiliation:
            name:National Institute for Biologic Standards and Control
            address:
               name:National Institute for Biologic Standards and Control, Hertfordshire, UK
               type:PostalAddress
            type:Organization
      name:T. G. Allen-Mersh
      affiliation:
            name:Chelsea and Westminster Hospital
            address:
               name:Department of Gastrointestinal Surgery, Chelsea and Westminster Hospital, London, UK
               type:PostalAddress
            type:Organization
      name:W. A. Kmiot
      affiliation:
            name:Hammersmith Hospital
            address:
               name:Academic Department of Colorectal Surgery, Hammersmith Hospital, London, UK
               type:PostalAddress
            type:Organization
      name:A. A. Epenetos
      affiliation:
            name:St. George’s Hospital
            address:
               name:Antisoma Plc, St. George’s Hospital, London, UK
               type:PostalAddress
            type:Organization
      name:D. Snary
      affiliation:
            name:Imperial Cancer Research Fund
            address:
               name:Applied Development Laboratory, Imperial Cancer Research Fund, London, UK
               type:PostalAddress
            type:Organization
      name:W. F. Bodmer
      affiliation:
            name:Institute of Molecular Medicine
            address:
               name:Cancer and Immunogenetics Laboratory, Imperial Cancer Research Fund, Institute of Molecular Medicine, Oxford, UK
               type:PostalAddress
            type:Organization
PostalAddress:
      name:Academic Department of Colorectal Surgery, Hammersmith Hospital, London, UK
      name:School of Clinical Medicine and Research, University of the West Indies, Queen Elizabeth Hospital, Barbados
      name:St. Luke’s Cancer Centre, Royal Surrey County Hospital, Guildford, UK
      name:Applied Development Laboratory, Imperial Cancer Research Fund, London, UK
      name:National Institute for Biologic Standards and Control, Hertfordshire, UK
      name:Antisoma Plc, St. George’s Hospital, London, UK
      name:Applied Development Laboratory, Imperial Cancer Research Fund, London, UK
      name:National Institute for Biologic Standards and Control, Hertfordshire, UK
      name:Department of Gastrointestinal Surgery, Chelsea and Westminster Hospital, London, UK
      name:Academic Department of Colorectal Surgery, Hammersmith Hospital, London, UK
      name:Antisoma Plc, St. George’s Hospital, London, UK
      name:Applied Development Laboratory, Imperial Cancer Research Fund, London, UK
      name:Cancer and Immunogenetics Laboratory, Imperial Cancer Research Fund, Institute of Molecular Medicine, Oxford, UK
WebPageElement:
      isAccessibleForFree:
      cssSelector:.main-content

External Links {🔗}(133)

Analytics and Tracking {📊}

Google Tag Manager

Libraries {📚}

Clipboard.js
Prism.js

CDN Services {📦}

Crossref

4.63s.

LINK . SPRINGER . COM {}